Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalBMRN +0.06%79 Equity-to-Asset is 0.54 as of Jun. 2026, which is 24% below its 10-year median of 0.71. GuruFocus rates BMRN with a GF Score™ of 79/100 and a GF Value™ of $85.03 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, BioMarin Pharmaceutical ranks worse than 64.31% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
BioMarin Pharmaceutical Equity-to-Asset Related Terms
BioMarin Pharmaceutical Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMRN vs MDGL, CORT, ARWR: Equity-to-Asset Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
BioMarin Pharmaceutical's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (BMRN) has a Equity-to-Asset of 0.54 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioMarin Pharmaceutical and its competitors. This is 24% below median its historical median of 0.71. Over the past decade, BioMarin Pharmaceutical's Equity-to-Asset has ranged from 0.54 to 0.81. According to the industry distribution chart, BioMarin Pharmaceutical ranks #908 out of 1412 companies in the Biotechnology industry, placing it in the top 64.3%.
Is BioMarin Pharmaceutical's Equity-to-Asset too high?
BioMarin Pharmaceutical's current Equity-to-Asset of 0.54 is 24% below median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 0.81. The Biotechnology industry median Equity-to-Asset is 0.69. BioMarin Pharmaceutical's value of 0.54 is 21.7% below this industry median. Based on the distribution chart, BioMarin Pharmaceutical ranks #908 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Equity-to-Asset compare to MDGL and CORT?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #908 out of 1412 companies for Equity-to-Asset. This places BioMarin Pharmaceutical in the lower half of its industry. The industry median Equity-to-Asset is 0.69. BioMarin Pharmaceutical's value of 0.54 is 21.7% below this benchmark. Historically, BioMarin Pharmaceutical's own Equity-to-Asset has ranged from 0.54 to 0.81 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.69, BioMarin Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMarin Pharmaceutical's current Equity-to-Asset of 0.54 is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on BioMarin Pharmaceutical and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMarin Pharmaceutical's current Equity-to-Asset is 0.54, which is 24% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $85.03, compared to a current price of $64.50 — trading 24.1% below its estimated fair value. The current Equity-to-Asset is 0.54, which is 24% below median its 10-year median of 0.71 and 21.7% below the Biotechnology industry median of 0.69. BioMarin Pharmaceutical's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current Equity-to-Asset is 0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of $64.50 is trading 24.1% below its estimated GF Value™ of $85.03.
GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.
Key valuation signals for BMRN:
Equity-to-Asset: 0.54 (24% below median its 10-year median of 0.71)
GF Value™: $85.03 vs. price of $64.50 (24.1% below fair value)
Industry Position: 21.7% below the Biotechnology median (#908 of 1412)
No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score
Get the complete analysis for BMRN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRN has been successfully added to your 
